{"hands_on_practices": [{"introduction": "A vaccine's effectiveness is profoundly influenced by how it presents antigen to the immune system. Different platforms, like mRNA and viral vectors, lead to different antigen expression dynamics. This exercise uses a simple kinetic model to quantify how the persistence of an antigen, a key factor in driving robust germinal center reactions, can be compared between vaccine technologies using the concept of Area Under the Curve (AUC) [@problem_id:2808234]. By working through this calculation, you will gain a quantitative appreciation for how platform choices can shape the initial phase of the immune response.", "problem": "A central determinant of germinal center (GC) dynamics is the persistence of antigen displayed to B cell receptors on follicular dendritic cells. Consider two vaccine platforms that deliver equal antigen-coding payloads, one as messenger ribonucleic acid (mRNA) and the other as a replication-defective viral vector. Assume the following foundational principles and definitions hold:\n\n1. The abundance of intact antigen-coding template within transduced cells decays exponentially with a platform-specific first-order rate constant $k$, related to the template half-life $t_{1/2}$ via $k = \\frac{\\ln 2}{t_{1/2}}$.\n2. The instantaneous antigen availability to B cells, denoted $S(t)$, is proportional to the remaining intact template, so $S(t) = S_{0}\\exp(-k t)$ for $t \\ge 0$, where $S_{0}$ is the initial antigen availability. Equal antigen payloads imply equal $S_{0}$ across platforms.\n3. Early GC dynamics are antigen-limited within a fixed observation window of $T$ days, so the integrated antigen availability over $[0,T]$, defined as $\\mathrm{AUC}(T) \\equiv \\int_{0}^{T} S(t)\\, dt$, is a first-order predictor of GC duration and magnitude.\n\nLet the mRNA platform have template half-life $t_{1/2}^{(\\mathrm{mRNA})} = $ $1$ day and the viral vector platform have $t_{1/2}^{(\\mathrm{vector})} = $ $3$ days. Take the observation window to be $T = $ $10$ days.\n\nStarting from the above principles, derive an expression for $\\mathrm{AUC}(T)$ for each platform and compute the ratio\n$$\nR \\equiv \\frac{\\mathrm{AUC}^{(\\mathrm{vector})}(T)}{\\mathrm{AUC}^{(\\mathrm{mRNA})}(T)}.\n$$\nReport $R$ as a dimensionless number rounded to four significant figures. Based on first principles, this ratio serves as a proxy for the relative expected GC duration over the stated window; however, you must report only the numerical value of $R$ as your final answer.", "solution": "The problem presented is a valid exercise in quantitative biological modeling. It is well-posed, scientifically grounded, and contains all necessary information for a unique solution. We will proceed with the derivation as requested.\n\nThe problem states that antigen availability, $S(t)$, decays exponentially following the first-order kinetics:\n$$\nS(t) = S_{0}\\exp(-k t)\n$$\nwhere $S_{0}$ is the initial antigen availability at time $t=0$, and $k$ is the decay rate constant. The constant $k$ is related to the half-life of the antigen-coding template, $t_{1/2}$, by the expression:\n$$\nk = \\frac{\\ln 2}{t_{1/2}}\n$$\nThe problem defines the integrated antigen availability over an observation window $[0, T]$ as the Area Under the Curve, $\\mathrm{AUC}(T)$:\n$$\n\\mathrm{AUC}(T) = \\int_{0}^{T} S(t) \\, dt\n$$\nFirst, we derive a general expression for $\\mathrm{AUC}(T)$ by integrating the function $S(t)$:\n$$\n\\mathrm{AUC}(T) = \\int_{0}^{T} S_{0}\\exp(-k t) \\, dt\n$$\nSince $S_{0}$ is a constant, it can be moved outside the integral:\n$$\n\\mathrm{AUC}(T) = S_{0} \\int_{0}^{T} \\exp(-k t) \\, dt\n$$\nThe integral of the exponential function is:\n$$\n\\mathrm{AUC}(T) = S_{0} \\left[ -\\frac{1}{k} \\exp(-k t) \\right]_{0}^{T}\n$$\nEvaluating the definite integral at the limits $t=T$ and $t=0$:\n$$\n\\mathrm{AUC}(T) = S_{0} \\left( \\left(-\\frac{1}{k} \\exp(-k T)\\right) - \\left(-\\frac{1}{k} \\exp(-k \\cdot 0)\\right) \\right)\n$$\n$$\n\\mathrm{AUC}(T) = S_{0} \\left( -\\frac{1}{k} \\exp(-k T) + \\frac{1}{k} \\exp(0) \\right)\n$$\nSince $\\exp(0) = 1$, we can simplify the expression:\n$$\n\\mathrm{AUC}(T) = \\frac{S_{0}}{k} (1 - \\exp(-k T))\n$$\nThis is the general expression for the integrated antigen availability.\n\nNext, we must calculate the specific decay constants for the two vaccine platforms, mRNA and viral vector, using the provided half-lives.\nFor the mRNA platform, $t_{1/2}^{(\\mathrm{mRNA})} = 1$ day. The corresponding decay constant is:\n$$\nk_{\\mathrm{mRNA}} = \\frac{\\ln 2}{t_{1/2}^{(\\mathrm{mRNA})}} = \\frac{\\ln 2}{1} = \\ln 2 \\text{ day}^{-1}\n$$\nFor the viral vector platform, $t_{1/2}^{(\\mathrm{vector})} = 3$ days. The corresponding decay constant is:\n$$\nk_{\\mathrm{vector}} = \\frac{\\ln 2}{t_{1/2}^{(\\mathrm{vector})}} = \\frac{\\ln 2}{3} \\text{ day}^{-1}\n$$\nNow, we can write the specific expressions for $\\mathrm{AUC}(T)$ for each platform, using the observation window $T = 10$ days. The problem states that the initial antigen availability $S_{0}$ is the same for both platforms.\n\nFor the mRNA platform:\n$$\n\\mathrm{AUC}^{(\\mathrm{mRNA})}(10) = \\frac{S_{0}}{k_{\\mathrm{mRNA}}} (1 - \\exp(-k_{\\mathrm{mRNA}} \\cdot 10)) = \\frac{S_{0}}{\\ln 2} (1 - \\exp(-10 \\ln 2))\n$$\nFor the viral vector platform:\n$$\n\\mathrm{AUC}^{(\\mathrm{vector})}(10) = \\frac{S_{0}}{k_{\\mathrm{vector}}} (1 - \\exp(-k_{\\mathrm{vector}} \\cdot 10)) = \\frac{S_{0}}{(\\ln 2)/3} (1 - \\exp\\left(-\\frac{10 \\ln 2}{3}\\right)) = \\frac{3 S_{0}}{\\ln 2} (1 - \\exp\\left(-\\frac{10}{3} \\ln 2\\right))\n$$\nThe problem requires the computation of the ratio $R$:\n$$\nR = \\frac{\\mathrm{AUC}^{(\\mathrm{vector})}(10)}{\\mathrm{AUC}^{(\\mathrm{mRNA})}(10)}\n$$\nSubstituting the derived expressions:\n$$\nR = \\frac{\\frac{3 S_{0}}{\\ln 2} (1 - \\exp(-\\frac{10}{3} \\ln 2))}{\\frac{S_{0}}{\\ln 2} (1 - \\exp(-10 \\ln 2))}\n$$\nThe term $\\frac{S_{0}}{\\ln 2}$ cancels from the numerator and the denominator, simplifying the expression for $R$:\n$$\nR = \\frac{3 (1 - \\exp(-\\frac{10}{3} \\ln 2))}{1 - \\exp(-10 \\ln 2)}\n$$\nTo evaluate this expression, we use the identity $a \\exp(b \\ln c) = a c^b$.\n$$\n\\exp(-10 \\ln 2) = 2^{-10}\n$$\n$$\n\\exp\\left(-\\frac{10}{3} \\ln 2\\right) = 2^{-10/3}\n$$\nSubstituting these back into the expression for $R$:\n$$\nR = \\frac{3 (1 - 2^{-10/3})}{1 - 2^{-10}}\n$$\nWe now compute the numerical value. We know $2^{10} = 1024$.\n$$\nR = \\frac{3 (1 - \\frac{1}{2^{10/3}})}{1 - \\frac{1}{1024}} = \\frac{3 (1 - (1024)^{-1/3})}{1023/1024}\n$$\nCalculating the values:\n$1 - (1024)^{-1/3} \\approx 1 - 0.09921252 \\approx 0.90078748$\n$1 - 1/1024 = 1023/1024 \\approx 0.99902344$\nThus,\n$$\nR \\approx \\frac{3 \\times 0.90078748}{0.99902344} \\approx \\frac{2.70236244}{0.99902344} \\approx 2.7050106\n$$\nRounding the result to four significant figures, as instructed, yields $2.705$.\nThe longer half-life of the viral vector template results in a more sustained antigen presence, leading to a significantly larger integrated antigen availability over the specified $10$-day window compared to the mRNA platform. This ratio $R$ quantifies that relative advantage within the confines of the model.", "answer": "$$\\boxed{2.705}$$", "id": "2808234"}, {"introduction": "Following antigen presentation, the germinal center becomes the site of a remarkable evolutionary process: affinity maturation. Here, B cells with higher-affinity antibodies are selectively expanded, leading to a more effective memory response. This practice delves into the mathematical heart of this process, using a model adapted from population genetics to derive the change in mean antibody affinity in a single round of selection [@problem_id:2808265]. This derivation reveals how selection pressure and the existing variation within the B cell pool combine to drive the evolution of better antibodies.", "problem": "Consider affinity maturation of B cells in the Germinal Center (GC) during a vaccine response. Let the survival probability of a clone with antibody affinity $a$ in a single GC selection round be given by the logistic function $s(a)=\\frac{1}{1+\\exp\\!\\left(-\\beta\\,(a-a_{0})\\right)}$, where $\\beta>0$ captures selection steepness and $a_{0}$ is a threshold affinity determined by antigen availability and T cell help. Assume that before selection the distribution of affinities is described by a probability density $f(a)$ with finite mean $\\bar{a}$ and variance $\\sigma_{a}^{2}$, and that $f(a)$ is sufficiently narrow that a first-order expansion around $\\bar{a}$ is accurate.\n\nUnder a simple replicator dynamic for viability selection, the post-selection affinity density is $f'(a)=\\dfrac{s(a)\\,f(a)}{\\int s(x)\\,f(x)\\,dx}$. Starting from the definitions of expectation under weighted sampling, derive the leading-order change in the mean affinity after one selection round,\n$$\\Delta \\bar{a}=\\bar{a}'-\\bar{a},$$\nexpressed entirely in terms of $\\beta$, $a_{0}$, $\\bar{a}$, and $\\sigma_{a}^{2}$, valid to first order in $\\sigma_{a}^{2}$ (that is, neglecting terms of order $\\sigma_{a}^{3}$ and higher). Your final answer must be a single closed-form analytic expression. Do not include any units.", "solution": "The problem statement is first validated for scientific soundness, self-consistency, and clarity.\n\nGivens are extracted as:\n- Survival probability as a function of affinity $a$: $s(a)=\\frac{1}{1+\\exp(-\\beta(a-a_{0}))}$.\n- Selection steepness: $\\beta > 0$.\n- Threshold affinity: $a_0$.\n- Pre-selection affinity probability density function (PDF): $f(a)$.\n- Mean of $f(a)$: $\\bar{a}$.\n- Variance of $f(a)$: $\\sigma_{a}^{2}$.\n- Post-selection affinity PDF: $f'(a)=\\dfrac{s(a)\\,f(a)}{\\int s(x)\\,f(x)\\,dx}$.\n- Change in mean affinity: $\\Delta \\bar{a}=\\bar{a}'-\\bar{a}$.\n- Assumption: $f(a)$ is narrow, justifying a first-order expansion around $\\bar{a}$. The final result should be valid to first order in $\\sigma_{a}^{2}$.\n\nThe problem is scientifically grounded, using standard models from theoretical immunology and population genetics (replicator dynamics, logistic fitness function). It is well-posed, with a clear objective and sufficient information. The language is precise and objective. Therefore, the problem is deemed valid and a solution will be derived.\n\nThe mean affinity after one round of selection, $\\bar{a}'$, is the expectation of $a$ with respect to the post-selection distribution $f'(a)$:\n$$ \\bar{a}' = \\int a f'(a) da = \\int a \\frac{s(a)f(a)}{\\int s(x)f(x)dx} da $$\nThis can be written as the ratio of expectations with respect to the pre-selection distribution $f(a)$:\n$$ \\bar{a}' = \\frac{\\langle a s(a) \\rangle}{\\langle s(a) \\rangle} $$\nwhere $\\langle \\cdot \\rangle$ denotes an expectation over the distribution $f(a)$.\n\nThe change in mean affinity, $\\Delta \\bar{a}$, is given by:\n$$ \\Delta \\bar{a} = \\bar{a}' - \\bar{a} = \\frac{\\langle a s(a) \\rangle}{\\langle s(a) \\rangle} - \\bar{a} = \\frac{\\langle a s(a) \\rangle - \\bar{a} \\langle s(a) \\rangle}{\\langle s(a) \\rangle} $$\nRecognizing that $\\bar{a} = \\langle a \\rangle$, we can write the numerator as:\n$$ \\langle a s(a) \\rangle - \\langle a \\rangle \\langle s(a) \\rangle = \\text{Cov}(a, s(a)) $$\nThis is the covariance between affinity $a$ and survival probability $s(a)$. Therefore, we have the expression:\n$$ \\Delta \\bar{a} = \\frac{\\text{Cov}(a, s(a))}{\\langle s(a) \\rangle} $$\nThis is a specific form of the Price equation for quantitative traits.\n\nTo evaluate the covariance and the average survival, we use the assumption that the affinity distribution $f(a)$ is narrow. This allows us to approximate $s(a)$ with a Taylor series expansion around the mean affinity $\\bar{a}$:\n$$ s(a) \\approx s(\\bar{a}) + s'(\\bar{a})(a-\\bar{a}) + \\frac{1}{2}s''(\\bar{a})(a-\\bar{a})^2 + \\dots $$\nwhere primes denote derivatives with respect to $a$.\n\nFirst, we evaluate the numerator, $\\text{Cov}(a, s(a))$, which is defined as $\\langle (a-\\bar{a})s(a) \\rangle$:\n$$ \\text{Cov}(a, s(a)) = \\int (a-\\bar{a}) s(a) f(a) da $$\nSubstituting the Taylor expansion for $s(a)$:\n$$ \\text{Cov}(a, s(a)) \\approx \\int (a-\\bar{a}) \\left[ s(\\bar{a}) + s'(\\bar{a})(a-\\bar{a}) + \\frac{1}{2}s''(\\bar{a})(a-\\bar{a})^2 + \\dots \\right] f(a) da $$\nIntegrating term-by-term:\n$$ \\text{Cov}(a, s(a)) \\approx s(\\bar{a}) \\int (a-\\bar{a})f(a)da + s'(\\bar{a}) \\int (a-\\bar{a})^2 f(a)da + \\frac{s''(\\bar{a})}{2} \\int (a-\\bar{a})^3 f(a)da + \\dots $$\nThe integrals are the central moments of the distribution $f(a)$:\n- $\\int (a-\\bar{a})f(a)da = \\mu_1 = 0$ (the first central moment is zero by definition).\n- $\\int (a-\\bar{a})^2 f(a)da = \\mu_2 = \\sigma_a^2$ (the second central moment is the variance).\n- $\\int (a-\\bar{a})^3 f(a)da = \\mu_3$. This term is of order $\\sigma_a^3$ or higher and can be neglected for a first-order calculation in $\\sigma_a^2$.\n\nThus, to leading order, the covariance is:\n$$ \\text{Cov}(a, s(a)) \\approx s'(\\bar{a}) \\sigma_a^2 $$\nThis term is of order $\\sigma_a^2$.\n\nNext, we evaluate the denominator, $\\langle s(a) \\rangle$:\n$$ \\langle s(a) \\rangle = \\int s(a) f(a) da \\approx \\int \\left[ s(\\bar{a}) + s'(\\bar{a})(a-\\bar{a}) + \\frac{1}{2}s''(\\bar{a})(a-\\bar{a})^2 + \\dots \\right] f(a) da $$\n$$ \\langle s(a) \\rangle \\approx s(\\bar{a}) \\int f(a)da + s'(\\bar{a}) \\int (a-\\bar{a})f(a)da + \\dots = s(\\bar{a}) \\cdot 1 + s'(\\bar{a}) \\cdot 0 + O(\\sigma_a^2) $$\nThe leading order term in the denominator is simply $s(\\bar{a})$, which is of order $1$. The next non-zero term is $\\frac{1}{2} s''(\\bar{a})\\sigma_a^2$, which is of order $\\sigma_a^2$.\n\nNow, we compute the ratio for $\\Delta \\bar{a}$:\n$$ \\Delta \\bar{a} \\approx \\frac{s'(\\bar{a})\\sigma_a^2}{s(\\bar{a}) + O(\\sigma_a^2)} $$\nTo find the expression valid to first order in $\\sigma_a^2$, we take the leading order term from the numerator (order $\\sigma_a^2$) and the leading order term from the denominator (order $1$). Any higher-order terms in the denominator would, upon expansion, contribute terms of order $(\\sigma_a^2)^2 = \\sigma_a^4$ or higher to the final expression for $\\Delta \\bar{a}$. Thus, we have:\n$$ \\Delta \\bar{a} \\approx \\frac{s'(\\bar{a})}{s(\\bar{a})}\\sigma_a^2 $$\n\nFinally, we must express this in terms of the given parameters. The survival function is $s(a)=\\frac{1}{1+\\exp(-\\beta(a-a_{0}))}$. Its derivative is:\n$$ s'(a) = \\frac{d}{da} \\left(1+\\exp(-\\beta(a-a_{0}))\\right)^{-1} = -1 \\left(1+\\exp(-\\beta(a-a_{0}))\\right)^{-2} \\cdot \\exp(-\\beta(a-a_{0})) \\cdot (-\\beta) $$\n$$ s'(a) = \\frac{\\beta \\exp(-\\beta(a-a_{0}))}{\\left(1+\\exp(-\\beta(a-a_{0}))\\right)^2} $$\nThis can be written in the well-known form $s'(a) = \\beta s(a) (1-s(a))$.\nSubstituting this into our expression for $\\Delta \\bar{a}$:\n$$ \\Delta \\bar{a} = \\frac{\\beta s(\\bar{a}) (1-s(\\bar{a}))}{s(\\bar{a})} \\sigma_a^2 = \\beta (1-s(\\bar{a})) \\sigma_a^2 $$\nNow we substitute the expression for $s(\\bar{a})$:\n$$ 1-s(\\bar{a}) = 1 - \\frac{1}{1+\\exp(-\\beta(\\bar{a}-a_0))} = \\frac{1+\\exp(-\\beta(\\bar{a}-a_0)) - 1}{1+\\exp(-\\beta(\\bar{a}-a_0))} = \\frac{\\exp(-\\beta(\\bar{a}-a_0))}{1+\\exp(-\\beta(\\bar{a}-a_0))} $$\nTo simplify, we multiply the numerator and denominator by $\\exp(\\beta(\\bar{a}-a_0))$:\n$$ 1-s(\\bar{a}) = \\frac{1}{\\exp(\\beta(\\bar{a}-a_0)) + 1} $$\nTherefore, the final expression for the change in mean affinity is:\n$$ \\Delta \\bar{a} = \\frac{\\beta \\sigma_a^2}{1+\\exp(\\beta(\\bar{a}-a_0))} $$\nThis expression is in terms of $\\beta$, $a_0$, $\\bar{a}$, and $\\sigma_a^2$, and is valid to first order in $\\sigma_a^2$.", "answer": "$$ \\boxed{\\frac{\\beta \\sigma_{a}^{2}}{1+\\exp(\\beta(\\bar{a}-a_{0}))}} $$", "id": "2808265"}, {"introduction": "The ultimate goal of many vaccination programs is not just to protect individuals, but to control or eliminate a pathogen at the population level through herd protection. This requires understanding how a vaccine's effects on individual susceptibility and transmissibility translate to overall disease dynamics. This problem challenges you to build an epidemiological model from first principles to calculate the effective reproduction number ($R_{\\mathrm{eff}}$) in a partially vaccinated population [@problem_id:2808235]. Completing this exercise will solidify your understanding of how immunological memory, quantified by vaccine efficacy, impacts public health.", "problem": "A population faces a newly introduced respiratory virus with basic reproduction number $R_0$, defined as the dominant eigenvalue (spectral radius) of the next-generation operator in a wholly susceptible, unvaccinated population under proportionate mixing. A vaccine induces immunological memory that reduces susceptibility to infection via recall responses of memory B cells and T cells, quantified by efficacy against infection $E_s$ (so that a vaccinated recipient’s susceptibility is multiplied by $1 - E_s$), and reduces onward transmission upon breakthrough infection via more rapid viral clearance and lower viral load, quantified by efficacy against transmission $E_t$ (so that an infected vaccinated individual’s infectiousness is multiplied by $1 - E_t$). Vaccination coverage is $v$ (fraction vaccinated), and contacts are assumed homogeneous with proportionate mixing between vaccinated and unvaccinated individuals. There is no waning within the time scale considered, and vaccine effects on susceptibility and infectiousness act multiplicatively at each transmission event. \n\nStarting from the fundamental definitions of the basic reproduction number $R_0$ and of the effective reproduction number as the spectral radius of the next-generation operator in the vaccine-stratified population, and using only the assumptions stated above, derive an analytic expression for the effective reproduction number $R_{\\mathrm{eff}}$ in terms of $R_0$, $v$, $E_s$, and $E_t$. Then evaluate $R_{\\mathrm{eff}}$ for $R_0 = 3$, $E_s = 0.7$, $E_t = 0.5$, and $v = 0.6$. Finally, based on your computed $R_{\\mathrm{eff}}$, determine whether herd protection (defined by $R_{\\mathrm{eff}} < 1$) is achieved under these conditions. Express the value of $R_{\\mathrm{eff}}$ as a unitless decimal; no rounding is required.", "solution": "We begin with the definition that the basic reproduction number $R_0$ is the dominant eigenvalue (spectral radius) of the next-generation operator $\\mathcal{K}$ in a wholly susceptible, unvaccinated population under proportionate mixing. In a population stratified into vaccinated and unvaccinated individuals, we consider a $2 \\times 2$ next-generation matrix $K$ whose entry $K_{h,g}$ is the expected number of new infections in recipient group $h \\in \\{\\mathrm{V}, \\mathrm{U}\\}$ caused by a single infectious individual in source group $g \\in \\{\\mathrm{V}, \\mathrm{U}\\}$ over its entire infectious period, under proportionate mixing. Here $\\mathrm{V}$ denotes vaccinated and $\\mathrm{U}$ denotes unvaccinated.\n\nUnder the assumptions:\n- a vaccinated recipient’s susceptibility is multiplied by $1 - E_s$ relative to baseline, and an unvaccinated recipient’s susceptibility is $1$;\n- a vaccinated source’s infectiousness is multiplied by $1 - E_t$ relative to baseline, and an unvaccinated source’s infectiousness is $1$;\n- contacts are homogeneous and proportionate, so the probability a random contact partner is vaccinated is $v$ and unvaccinated is $1 - v$,\n\nwe can factor each $K_{h,g}$ as the baseline reproduction potential $R_0$ multiplied by three independent factors: (i) the probability that a random contact falls into recipient group $h$, (ii) the susceptibility factor of group $h$, and (iii) the infectiousness factor of source group $g$. This gives\n$$\nK_{h,g} \\;=\\; R_0 \\times p_h \\times f_s(h) \\times f_t(g),\n$$\nwhere $p_{\\mathrm{V}} = v$, $p_{\\mathrm{U}} = 1 - v$, $f_s(\\mathrm{V}) = 1 - E_s$, $f_s(\\mathrm{U}) = 1$, $f_t(\\mathrm{V}) = 1 - E_t$, and $f_t(\\mathrm{U}) = 1$.\n\nThus, the matrix $K$ can be written as an outer product:\n$$\nK \\;=\\; \\bigl(R_0 \\, \\mathbf{u}\\bigr)\\, \\mathbf{w}^{\\top},\n$$\nwith\n$$\n\\mathbf{u} \\;=\\; \\begin{pmatrix} p_{\\mathrm{V}} f_s(\\mathrm{V}) \\\\ p_{\\mathrm{U}} f_s(\\mathrm{U}) \\end{pmatrix}\n\\;=\\; \\begin{pmatrix} v (1 - E_s) \\\\ 1 - v \\end{pmatrix},\n\\qquad\n\\mathbf{w} \\;=\\; \\begin{pmatrix} f_t(\\mathrm{V}) \\\\ f_t(\\mathrm{U}) \\end{pmatrix}\n\\;=\\; \\begin{pmatrix} 1 - E_t \\\\ 1 \\end{pmatrix}.\n$$\nFor an outer-product matrix $K = (R_0 \\mathbf{u}) \\mathbf{w}^{\\top}$, the nonzero eigenvalue (and hence the spectral radius) is\n$$\nR_{\\mathrm{eff}} \\;=\\; \\rho(K) \\;=\\; R_0 \\, \\mathbf{w}^{\\top}\\mathbf{u} \\;=\\; R_0 \\left[ f_t(\\mathrm{V}) \\, p_{\\mathrm{V}} f_s(\\mathrm{V}) \\;+\\; f_t(\\mathrm{U}) \\, p_{\\mathrm{U}} f_s(\\mathrm{U}) \\right].\n$$\nSubstituting the expressions for the factors yields\n$$\nR_{\\mathrm{eff}} \\;=\\; R_0 \\left[ (1 - E_t)\\, v (1 - E_s) \\;+\\; 1 \\cdot (1 - v) \\cdot 1 \\right]\n\\;=\\; R_0 \\left[ (1 - v) \\;+\\; v (1 - E_s)(1 - E_t) \\right].\n$$\n\nWe now evaluate this expression for $R_0 = 3$, $E_s = 0.7$, $E_t = 0.5$, and $v = 0.6$. First compute the bracketed term:\n$$\n(1 - v) \\;=\\; 1 - 0.6 \\;=\\; 0.4,\n$$\n$$\n(1 - E_s)(1 - E_t) \\;=\\; (1 - 0.7)(1 - 0.5) \\;=\\; 0.3 \\times 0.5 \\;=\\; 0.15,\n$$\n$$\nv (1 - E_s)(1 - E_t) \\;=\\; 0.6 \\times 0.15 \\;=\\; 0.09,\n$$\nso\n$$\n(1 - v) + v (1 - E_s)(1 - E_t) \\;=\\; 0.4 + 0.09 \\;=\\; 0.49.\n$$\nTherefore,\n$$\nR_{\\mathrm{eff}} \\;=\\; R_0 \\times 0.49 \\;=\\; 3 \\times 0.49 \\;=\\; 1.47.\n$$\n\nTo assess herd protection, we compare $R_{\\mathrm{eff}}$ to $1$. Because $1.47 > 1$, herd protection (defined by $R_{\\mathrm{eff}} < 1$) is not achieved under these conditions; sustained transmission remains possible. The required numerical output is the value of $R_{\\mathrm{eff}}$ as a unitless decimal, which we have computed exactly as $1.47$.", "answer": "$$\\boxed{1.47}$$", "id": "2808235"}]}